| |
| | PCB Cancer Dose Response Assessment |
 | | Dose was expressed as a lifetime daily average (U.S. EPA, 1986a, 1992a), calculated from weekly body weight measurements and food consumption estimates (Keenan and Stickney, 1996). |
 | | Response was taken as the incidence of hepatocellular adenomas or carcinomas; combining adenomas and carcinomas reflects guidance of the National Toxicology Program (McConnell et al., 1986) and the observed progression of hepatocellular adenomas to carcinomas (Norback and Weltman, 1985). |
 | | This difference is attributable to three factors, each responsible for reducing the slope by approximately one-third: the rat liver tumor reevaluation (Moore et al., 1994), use of the new cross-species scaling factor (U.S. EPA, 1992b), and not using a time-weighted average dose (see previous footnote). |
| www.cqs.com /epa/pcb/pcb_cdra.htm (16586 words) |
|